Brief: Egoo Health Says Breakthrough Precision In Diabetes Biomarker Test
15/01/2026 07:43
Jan 15 (Reuters) - Qlife Holding AB QLIFE.ST: EGOO HEALTH ACHIEVES BREAKTHROUGH PRECISION IN KEY DIABETES BIOMARKER TEST, PAVING THE WAY FOR PARTNERSHIPS EGOO HBA1C BLOOD TEST FOR DIABETES MANAGEMENT HAS ACHIEVED BEST-IN-CLASS PRECISION WITH A COEFFICIENT OF VARIATION (CV) BELOW 3% Source text: ID:nWkr1CQyNp Further company coverage: QLIFE.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Qlife Holding AB
See all newsAdvisory: Alerts on Qlife's agreement with global pharma company withdrawn
Brief: Qlife Holding Enters Feasibility Deal With Pharma Co For Egoo Health Biomarker
Brief: Qlife Holding Q1 EBITDA Loss SEK 5.5 Mln
Sweden's Qlife Q1 revenue drops, losses widen slightly
Brief: Qlife Holding Q4 EBITDA At SEK -1.6 Million